
BPC-157 5mg Regeneración
Recuperación relámpago.
La referencia absoluta de la recuperación. Un pentadecapéptido gástrico estudiado en investigación preclínica desde hace más de 30 años. Tendones, articulaciones, intestinos, mucosas — BPC-157 acelera la cicatrización tisular a un nivel nunca visto. El arma secreta de los atletas de alto nivel. Formato de protocolo flexible.
Inicio de los protocolos de investigación: 5 unidades, es decir 250 mcg al día (vial preparado con 1 ml de agua).
5 mg = el contenido del vial, no la dosis.Ver la preparación
- Certificado de análisis
- Stock en Francia
Pedido con su agua: enviado en estuche imantado
-10 % en cada envíoPause, salte o cancele en 1 clicSin compromiso, sin gastos ocultos
Sin cargo automático: pague cada envío con tarjeta, en Bitcoin (-5 % adicional) o por transferencia desde 100 €
Este producto contiene BPC-157. Los trabajos publicados abordan la angiogénesis, la formación de nuevos vasos sanguíneos. Ningún ensayo clínico humano aleatorizado ha caracterizado las contraindicaciones.
Las alertas teóricas descritas en los trabajos preclínicos afectan a los antecedentes de cáncer, en particular tumores sólidos muy vascularizados, al embarazo y la lactancia, y a las retinopatías proliferativas.
Tu kit completo
El vial por sí solo no puede usarse tal cual. Añada lo necesario para prepararlo:
Se compran juntos a menudo
Uso exclusivo en investigación (RUO) · Prohibido para uso humano o veterinario.
Lo esencial
Our BPC-157 5 mg vial is the ideal entry format for researchers wishing to initiate a first exploratory protocol without committing to large stock. With 5 mg of lyophilized peptide per vial at HPLC purity ≥98 %, this format suits short research cycles (10 to 20 days) and preliminary validations before moving to a more extended format. The certificate of analysis is published on this page, viewable before you order. BPC-157 5 mg is intended for independent researchers, experimental sports medicine clinics, and laboratories prioritizing maximum supply flexibility. Why choose the 5 mg format? Reduced initial investment, simple reconstitution (1 ml = 5 mg/ml), autonomy of 10 to 20 days at 250-500 mcg/day.
En detalle
The perfect pilot format to document a first phase before escalation.
Protocolo y preparación
| Agua añadida | Concentración | Marca de lectura |
|---|---|---|
| 1 ml | 5 mg/ml | 40 UI = 2 mg |
| 2 ml | 2,5 mg/ml | 40 UI = 1 mg |
El volumen de agua no cambia el producto, solo su concentración. Introduzca el agua despacio por la pared del vial, nunca directamente sobre el liofilizado, y luego gírelo suavemente sin agitar. Las marcas se dan sobre una jeringa de 1 ml graduada en 100 unidades.
Asepsia
Desinfecte las superficies y los tapones (alcohol al 70%).
Disolvente
Extraiga el volumen necesario de agua bacteriostática.
Introducción
Inyecte suavemente contra la pared del vial (evite el chorro directo sobre el polvo).
Solubilización
Haga rodar el vial suavemente. No lo agite con fuerza (riesgo de degradación).
Conservación de la solución Una vez reconstituido: 2-8°C (nevera).
Advertencia Herramienta teórica para manipulación química. No constituye un consejo médico.
Abrir la calculadora de dilución- La cantidad de polvo parece mínima. Un liofilizado ocupa unos pocos milímetros en el fondo del vial, a veces solo una película translúcida. El peso indicado está ahí.
- El polvo está compacto, pegado a la pared o al tapón. El transporte desplaza la torta liofilizada. No cambia nada en la reconstitución.
- El vial no lleva etiqueta individual. Es nuestro embalaje estándar, no un vial de menor calidad.
- Tras la reconstitución aparecen depósitos o filamentos. Es habitual, sobre todo con moléculas pequeñas. Deje que se asiente y haga rodar el vial entre las palmas, nunca lo agite.
- El paquete es neutro. Nada en el exterior indica el contenido ni el nombre de la marca.
Lo que no es normal: un vial agrietado, una cápsula sin engastar o un tapón que se mueve, polvo que se ha licuado o cambiado de color. En esos casos concretos, escríbanos con una foto y recuperamos el vial.
Recommended reconstitution: 1 ml bacteriostatic water for injection → final concentration 5 mg/ml. Procedure: 1) let the vial and diluent reach room temperature (15 minutes); 2) disinfect the vial stopper with 70% alcohol; 3) draw bacteriostatic water into a sterile syringe; 4) inject slowly along the inner wall of the vial; 5) gently swirl the vial until complete dissolution — never shake vigorously. Dosages reported in preclinical literature: documented human research protocols (outside authorized therapeutic framework) typically mention 250-500 mcg per day subcutaneously. At 5 mg/ml concentration, 250 mcg = 0.05 ml (5 units on 100 IU syringe) and 500 mcg = 0.1 ml (10 units). Autonomy: 5 mg allows approximately 20 days at 250 mcg/day, or 10 days at 500 mcg/day — ideal format for a 10- to 20-day pilot cycle. Post-reconstitution storage: refrigerator 2-8 degrees Celsius, 28-day usage window with bacteriostatic. On a short pilot cycle, the vial can be fully used well before the stability limit.
Datos técnicos
- Reconstitución
- 1 ml d'eau → 5 mg/ml. 5 UI = 250 mcg ; 10 UI = 500 mcg.
- Secuencia peptídica
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Fórmula molecular
- C62H98N16O22
- Peso molecular
- 1419.5 g/mol
- Número CAS
- 137525-51-0
- Forma física
- Poudre lyophilisée
- Solubilidad recomendada
- Eau bactériostatique, NaCl 0,9%
- Condiciones de conservación
- Au réfrigérateur (+2 à +8 °C), à l'abri de la lumière. En poudre, possible au congélateur pour une conservation longue. Une fois préparé : réfrigérateur, jamais au congélateur.
- Uso
- Reactivo de investigación, solo in vitro (RUO)
Conservación y manipulación
Lyophilized unreconstituted BPC-157 is stored in the fridge (+2 to +8 °C) in its original sealed packaging, protected from light and humidity; for long-term storage (over 3 months), a -20 °C freezer keeps it for up to 24 months. At refrigerated temperature (2-8 degrees Celsius), documented stability covers at least 12 months. At room temperature (below 25 degrees Celsius), the recommended duration for temporary transport or storage does not exceed 4 weeks. Once reconstituted with bacteriostatic water for injection, BPC-157 must imperatively be stored between 2 and 8 degrees Celsius. Post-reconstitution stability is documented in the literature for up to 28 days when bacteriostatic water (containing 0.9% benzyl alcohol) is used. With preservative-free sterile water, the usage window narrows to 5-7 days. The peptide is particularly sensitive to several deleterious factors: repeated freeze-thaw cycles (prefer aliquots for large volumes), direct UV light exposure, abrupt thermal variations, and contact with non-inert metallic surfaces. Freeze-thaw cycles should be limited to a maximum of three. The certificate of analysis is published on this page, viewable before you order. Optimal pH lies between 5.5 and 7.0: avoid any reconstitution in acidic (pH < 4) or basic (pH > 9) solution which would favour hydrolytic degradation of proline-proline bonds. Never refreeze an already-reconstituted solution: freeze/thaw cycles generate aggregates detectable by SEC-HPLC and decrease biological activity in rodent models. Packaging in type I borosilicate glass vial with siliconised butyl stopper limits peptide/container interactions and guarantees batch integrity for planned study duration.
Mecanismo de acción
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), derived from a body-protection sequence originally identified in human gastric juice. Its unusual stability in acidic environments sets it apart from conventional peptides: the literature has reported a meaningful half-life at pH 2 and resistance to digestive proteases, making it a unique subject of study within the regenerative research peptide class.
At the molecular level, preclinical models have suggested a multimodal mechanism. BPC-157 modulates the nitric oxide (NO) system via an eNOS / neuronal NOS axis, which according to published observations influences local vasodilation and tissue perfusion. Complementary work has documented activation of the VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) pathway, involved in angiogenesis, along with upregulation of early growth response genes (Egr-1) and the FAK-paxillin transcription factor in studied endothelial cells.
The peptide has also been reported to interact with central dopaminergic and serotonergic axes: rodent behavioral studies describe effects on neuroplasticity, GABAergic tone, and stress response. On the gastrointestinal front, literature has described mucosal barrier protection via modulation of endogenous prostaglandin (PGE2) and heat shock proteins (HSP70/90). These converging mechanisms position BPC-157 as a research peptide of particular interest in tissue-repair models (tendons, ligaments, skeletal muscle), traumatic brain injury (TBI) models, and experimental gastropathy.
It is critical to recall that all of this data comes from preclinical models (rodent, porcine, in vitro) and limited case studies. No marketing authorization exists for therapeutic human use: BPC-157 remains strictly a peptide for exploratory research.
Structurally, BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid pentadecapeptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, mass 1419.6 Da) derived from a protective sequence identified by Sikiric and colleagues (University of Zagreb) from a stable fragment of human gastric juice, pepsin-resistant (Sikirić et al., Eur J Pharmacol 1991, J Physiol Paris 1997). Its stability in gastric acid radically distinguishes BPC-157 from most naturally occurring proteolysis-sensitive peptides. Molecular pathways documented in preclinical research include: (1) activation of nitric oxide (NO) synthesis via L-arginine/eNOS pathway, (2) transcriptional upregulation of VEGF-A and FGF-2 favouring angiogenesis, (3) modulation of the Egr-1 early transcription factor involved in fibroblast proliferation, (4) interaction with 5-HT2A and dopaminergic receptors in some behavioural models, (5) stabilisation of endothelial function via eNOS modulation and reduction of oxidative stress (8-OH-dG, MDA).
Estudios y referencias
The BPC-157 preclinical corpus is dense and spans over two decades, driven primarily by the Sikiric group (Zagreb University School of Medicine). The main publications cover several converging experimental models.
Sikiric et al. (Journal of Physiology — Paris, 2001; DOI 10.1016/S0928-4257(01)00003-5) laid the initial mechanistic foundation, documenting gastric cytoprotection and mucosal barrier restoration in rats subjected to various chemical stressors (ethanol, NSAIDs, caustic agents). This foundational work was extended in Current Pharmaceutical Design (Sikiric et al. 2011; DOI 10.2174/138161211795589837), which synthesizes over 50 distinct animal models and positions BPC-157 as a "stable gastric pentadecapeptide" candidate.
On tendon repair, Staresinic et al. (Journal of Orthopaedic Research 2003; DOI 10.1016/S0736-0266(03)00016-X) reported in rats an acceleration of Achilles tendon healing after transection, with improved histological and biomechanical parameters versus control. Chang et al. (Journal of Applied Physiology 2011; DOI 10.1152/japplphysiol.00110.2011) extended these observations to the ischemia-reperfusion-injured quadriceps tendon.
In the cerebral field, Klicek et al. (Journal of Physiology and Pharmacology 2013) documented attenuation of post-traumatic lesions in a murine TBI model, with preservation of motor parameters assessed via neurological scale. Complementary work on MPTP neurotoxicity suggested a protective action on the nigrostriatal dopaminergic system.
On the cardiovascular side, Sikiric et al. (European Journal of Pharmacology 2016) reported effects on experimentally induced pulmonary hypertension and on ventricular arrhythmia in rats. Finally, colitis models (DSS-induced ulcerative colitis in mice) have documented restoration of intestinal mucosal integrity.
Critical limitations of the corpusThe vast majority of data comes from a limited number of laboratories, independent reproducibility studies are rare, and no large-scale randomized controlled phase 3 human clinical trial has been published or registered. BPC-157 remains in a regulatory gray zone and is strictly a preclinical research tool.
The rodent preclinical models documented for BPC-157 cover an exceptionally broad spectrum. In experimental orthopaedics: transected rat Achilles tendon (Staresinic 2003, Chang 2011), patellar tendon, lateral knee ligament, medial collateral ligament, rotator cuff tendon — restoration of collagenic fascicular organisation on histology and mechanical tension strength at 4-6 weeks. In experimental gastroenterology: gastric ulcers induced by ethanol, aspirin, indomethacin, duodenal cysteamine — ulcer index reduction of 60-90% depending on models. In experimental IBD: TNBS-induced colitis, DSS in C57BL/6J mice — decrease in histopathological scores and pro-inflammatory cytokines (TNF-α, IL-6, IL-1β). In experimental orthodontics: ligature-induced periodontitis, cuneiform bone fractures, rat calvaria defects. In cardiovascular: aortic aneurysm models, hepatic ischaemia-reperfusion, deep vein thrombosis. In neurology: closed head trauma, spinal cord hemisection, hepatic encephalopathy. All these studies are preclinical; no validated clinical data in humans is available for therapeutic use.
- 1
- 2
- 3
- 4
Péptidos similares
BPC-157 occupies a unique position within the regenerative research peptide class. Unlike TB-500 (Thymosin Beta-4 fragment), which acts primarily via G-actin sequestration and endothelial progenitor cell mobilization, BPC-157 exerts its action via an NO-dependent pathway and VEGFR2 modulation — two distinct but potentially complementary mechanisms, which is why research protocols sometimes combine both peptides (synergy documented in animal tendon repair models).
Compared to classical growth factors such as IGF-1 or GH (Growth Hormone), BPC-157 is distinguished by its local specificity and absence of marked endocrine systemic effects in studied models. GH and IGF-1 operate via generalized anabolic stimulation and mitogenesis, whereas BPC-157 appears to favor modulation of the tissue microenvironment (local angiogenesis, controlled inflammation, endothelial stabilization).
Compared to anti-inflammatory peptides such as LL-37 or cathelicidins, BPC-157 does not display direct antimicrobial activity but modulates the immune-vascular axis in a more refined manner. Compared to classical gastroprotective peptides such as sucralfate or proton pump inhibitors (PPIs), it acts via a completely different pathway: restoration of mucosal microcirculation rather than acid reduction or formation of a mechanical protective layer.
In our shop, BPC-157 is the most ordered recovery peptide, and one of the most documented in preclinical literature. Commercialization for human therapeutic use remains prohibited in France, Europe, and the United States, hence the importance of sourcing strictly intended for in vitro and ex vivo research.
Compared to other regenerative research peptides, BPC-157 sits in a specific segment: multi-organ systemic action with exceptional acid stability and versatility (documented PO, IP, SC, IM). TB-500 (synthetic thymosin β-4 fragment, LKKTETQ, 889 Da) shares tissue-healing indications but acts through a different mechanism (G-actin sequestration, Ac-SDKP anti-fibrosis). The BPC-157 + TB-500 combination is proposed in grey literature as complementary in preclinical tendon protocols. Compared to GHK-Cu (340 Da tripeptide), BPC-157 preferentially targets deep tissues and visceral healing, while GHK-Cu focuses on skin and dermal collagen production. Compared to IGF-1 LR3, BPC-157 does not directly stimulate cell proliferation via IGF-1R but acts indirectly via NO/VEGF pathways — distinct use profile.
Preguntas frecuentes
Is BPC-157 5 mg enough for a complete research cycle?
How do I reconstitute BPC-157 5 mg to obtain 5 mg/ml?
Why is BPC-157 considered stable in acidic environments?
Can BPC-157 be combined with TB-500 in research?
Which biological markers are studied in BPC-157 protocols?
Is your BPC-157 authentic and research-grade?
What is the delivery lead time in Europe?
What is the documented tolerance profile in preclinical studies?
Is BPC-157 stable at room temperature?
What HPLC purity is expected for a research-grade BPC-157 batch?
Does BPC-157 require reconstitution with specific bacteriostatic water?
La guía completaSíntesis de péptidos en fase sólida (SPPS): guía completa de Merrifield, Fmoc, Boc, resinas, reactivos de acoplamiento y control de calidadPrincipio de Merrifield, estrategias Fmoc y Boc, resinas (Wang, Rink amide, 2-clorotritilo), reactivos de acoplamiento (HBTU, HATU, DIC/HOBt), ciclo de síntesis, escisión con TFA, purificación por RP-HPLC, control de calidad por LC-MS y test de Kaiser. La referencia científica sobre la fabricación de péptidos sintéticos.Leer la guía Lee también:Analítica peptídica: LC-MS de alta resolución, RMN, HPLC y Edman - Guía completa de investigaciónBPC-157 vs TB-500: la comparativa 2026 de péptidos de investigación para la regeneración y reparación de tejidos
